F Recchia

Summary

Country: Italy

Publications

  1. doi request reprint Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC
    Francesco Di Costanzo
    Unit of Medical Oncology, Azienda Ospedaliero Universitaria Careggi, Viale Pieraccini 17, 50139 Florence, Italy
    J Natl Cancer Inst 100:388-98. 2008
  2. pmc Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC)
    F Di Costanzo
    U O di Oncologia Medica, Azienda Ospedaliera Careggi, Via Pieraccini 17, Florence, Italy
    Br J Cancer 93:185-9. 2005
  3. ncbi request reprint High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer
    R Mattioli
    S Croce Hospital, Medical Oncology Unit, Fano
    Ann Oncol 16:1147-51. 2005
  4. pmc Multicentre phase II study of bifractionated CPT-11 with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer pretreated with FOLFOX
    F Recchia
    Unita Operativa di Oncologia, Ospedale Civile di Avezzano, Italy
    Br J Cancer 91:1442-6. 2004
  5. ncbi request reprint Multicenter phase II study of CPT-11 fractionated over two days with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer
    F Recchia
    Unita operative di Oncologia, Ospedale Civile di Avezzano, Fondazione Carlo Ferri, Monterotondo, Roma, Italy
    Anticancer Res 23:2903-8. 2003
  6. ncbi request reprint Multicenter phase II study of fractionated bimonthly oxaliplatin with leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer, pre-treated with chemotherapy
    F Recchia
    Unita operative di Oncologia, Ospedale Civile di Avezzano, Universita degli studi de L Aquila, Italy
    Oncol Rep 10:65-9. 2003
  7. ncbi request reprint Primary chemotherapy in stage IV ovarian cancer. A prospective phase II study
    F Recchia
    Oncologic Unit, Avezzano, Italy
    Eur J Gynaecol Oncol 22:287-91. 2001
  8. ncbi request reprint Combined 5-fluorouracil infusion with fractionated epirubicin and cyclophosphamide in advanced breast cancer
    F Recchia
    Divisione di Oncologia, Ospedale Civile, Avezzano, Italy
    Am J Clin Oncol 24:392-6. 2001
  9. ncbi request reprint Phase II study of epirubicin, mitomycin C, and 5-fluorouracil in hormone-refractory prostatic carcinoma
    F Recchia
    Divisione di Oncologia, Ospedale Civile di Avezzano, Fondazione Ferri-C.R.O.F.I, Monterotonto, Rome, Italy
    Am J Clin Oncol 24:232-6. 2001
  10. ncbi request reprint Advanced colorectal cancer in elderly patients: tolerance and efficacy of leucovorin and fluorouracil bolus plus continuous infusion
    R Mattioli
    Medical Oncology Unit, S. Croce Hospital, I-61032 Fano, Italy
    Anticancer Res 21:489-92. 2001

Collaborators

Detail Information

Publications12

  1. doi request reprint Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC
    Francesco Di Costanzo
    Unit of Medical Oncology, Azienda Ospedaliero Universitaria Careggi, Viale Pieraccini 17, 50139 Florence, Italy
    J Natl Cancer Inst 100:388-98. 2008
    ..Complete surgical resection of gastric cancer is potentially curative, but long-term survival is poor...
  2. pmc Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC)
    F Di Costanzo
    U O di Oncologia Medica, Azienda Ospedaliera Careggi, Via Pieraccini 17, Florence, Italy
    Br J Cancer 93:185-9. 2005
    ..The median overall survival (OS) was 31 weeks (range 1-101 weeks) and 30 weeks (1-101 weeks). Toxicity was mild in both arms. This study does not show promising activity in terms of RR, PFS and OS for the double combination arm in APC...
  3. ncbi request reprint High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer
    R Mattioli
    S Croce Hospital, Medical Oncology Unit, Fano
    Ann Oncol 16:1147-51. 2005
    ..The proportion of elderly within the general population is increasing and the incidence of colorectal cancer increases with age. Oxaliplatin and 5-fluorouracil (FU) combination is active in this disease...
  4. pmc Multicentre phase II study of bifractionated CPT-11 with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer pretreated with FOLFOX
    F Recchia
    Unita Operativa di Oncologia, Ospedale Civile di Avezzano, Italy
    Br J Cancer 91:1442-6. 2004
    ..The bifractionated bimonthly schedule of CPT-11 plus 5-FU/LV showed substantial antitumour activity and was well tolerated in this group of patients with a poor prognosis, pretreated with the FOLFOX regimen...
  5. ncbi request reprint Multicenter phase II study of CPT-11 fractionated over two days with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer
    F Recchia
    Unita operative di Oncologia, Ospedale Civile di Avezzano, Fondazione Carlo Ferri, Monterotondo, Roma, Italy
    Anticancer Res 23:2903-8. 2003
    ....
  6. ncbi request reprint Multicenter phase II study of fractionated bimonthly oxaliplatin with leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer, pre-treated with chemotherapy
    F Recchia
    Unita operative di Oncologia, Ospedale Civile di Avezzano, Universita degli studi de L Aquila, Italy
    Oncol Rep 10:65-9. 2003
    ..The fractionated bimonthly schedule of L-OHP plus 5-FU-L, showed activity, with an acceptable toxicity profile, both in patients with MCC pre-treated with the 'de Gramont' regimen alone, or with this regimen associated with CPT-11...
  7. ncbi request reprint Primary chemotherapy in stage IV ovarian cancer. A prospective phase II study
    F Recchia
    Oncologic Unit, Avezzano, Italy
    Eur J Gynaecol Oncol 22:287-91. 2001
    ..Nine pathological CRs were observed. CONCLUSION: Neoadjuvant treatment with CBDCA with either CTX and EPI or Taxol is feasible and shows activity in OC...
  8. ncbi request reprint Combined 5-fluorouracil infusion with fractionated epirubicin and cyclophosphamide in advanced breast cancer
    F Recchia
    Divisione di Oncologia, Ospedale Civile, Avezzano, Italy
    Am J Clin Oncol 24:392-6. 2001
    ..7 months (range: 5.4--67.1+). Outpatient treatment with combined 5-FU c.i., epirubicin, and cyclophosphamide shows high activity in advanced breast cancer and gives prolonged remission with acceptable toxicity...
  9. ncbi request reprint Phase II study of epirubicin, mitomycin C, and 5-fluorouracil in hormone-refractory prostatic carcinoma
    F Recchia
    Divisione di Oncologia, Ospedale Civile di Avezzano, Fondazione Ferri-C.R.O.F.I, Monterotonto, Rome, Italy
    Am J Clin Oncol 24:232-6. 2001
    ..Thus the combination of E, MMC, and 5-FU shows activity in the treatment of HRPC, giving substantial palliation of symptoms. In one patient, PSA values remained low even when the tumor had progressed...
  10. ncbi request reprint Advanced colorectal cancer in elderly patients: tolerance and efficacy of leucovorin and fluorouracil bolus plus continuous infusion
    R Mattioli
    Medical Oncology Unit, S. Croce Hospital, I-61032 Fano, Italy
    Anticancer Res 21:489-92. 2001
    ..ADL and IADL indexes improved or remained stable in 82% of evaluable patients...
  11. ncbi request reprint 5-fluorouracil plus folinic acid with or without ifosfamide in advanced colorectal cancer: a phase II randomized trial
    A Sdrobolini
    Department of Medicine and Medical Oncology, Santa Maria Hospital, Terni, Italy
    Tumori 86:211-4. 2000
    ..CONCLUSIONS: IFO does not increase the activity of the 5-FU plus FA combination in advanced colorectal cancer...
  12. ncbi request reprint Low dose interleukin-2 and 13-cis-retinoic acid as maintenance therapy in patients with solid tumors responsive to chemotherapy
    F Recchia
    Unita Operativa di Oncologia, Ospedale Civile di Avezzano, Fondazione Carlo Ferri, Monterotondo, Italy
    J Exp Clin Cancer Res 22:135-43. 2003
    ..These data show that the administration of low-dose IL-2/RA determines, with a low toxicity, a sustained increase in the immunological parameters known to be prognostically relevant...